Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) was downgraded by Morgan Stanley from an “overweight” rating to an “equal weight” rating in a note issued to investors on Tuesday, Marketbeat reports. They currently have a $10.00 target price on the stock, down from their previous target price of $11.00. Morgan Stanley’s price target points to a potential upside of 21.65% from the stock’s current price.
A number of other equities analysts also recently commented on the stock. Robert W. Baird upped their target price on shares of Maravai LifeSciences from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday, May 9th. The Goldman Sachs Group increased their price objective on Maravai LifeSciences from $7.00 to $8.00 and gave the stock a “neutral” rating in a research note on Thursday, August 8th. Finally, UBS Group lifted their target price on Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.75.
Check Out Our Latest Analysis on Maravai LifeSciences
Maravai LifeSciences Price Performance
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.08) earnings per share for the quarter. Maravai LifeSciences had a negative return on equity of 4.28% and a negative net margin of 47.81%. The business had revenue of $73.40 million during the quarter, compared to the consensus estimate of $71.64 million. During the same quarter in the previous year, the company earned ($0.06) earnings per share. The company’s revenue for the quarter was up 6.5% compared to the same quarter last year. On average, sell-side analysts forecast that Maravai LifeSciences will post -0.15 EPS for the current year.
Insiders Place Their Bets
In other news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of Maravai LifeSciences stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $9.81, for a total value of $97,520,954.94. Following the transaction, the director now directly owns 20,150,005 shares in the company, valued at approximately $197,671,549.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.63% of the stock is owned by company insiders.
Institutional Trading of Maravai LifeSciences
Several hedge funds have recently modified their holdings of MRVI. Jump Financial LLC bought a new position in shares of Maravai LifeSciences during the 4th quarter worth approximately $225,000. Principal Financial Group Inc. increased its position in shares of Maravai LifeSciences by 3,349.6% during the first quarter. Principal Financial Group Inc. now owns 410,197 shares of the company’s stock worth $3,556,000 after purchasing an additional 398,306 shares in the last quarter. Performa Ltd US LLC lifted its holdings in shares of Maravai LifeSciences by 112.4% during the 4th quarter. Performa Ltd US LLC now owns 6,000 shares of the company’s stock valued at $39,000 after purchasing an additional 3,175 shares during the last quarter. Sivik Global Healthcare LLC purchased a new stake in shares of Maravai LifeSciences during the 4th quarter valued at $1,344,000. Finally, Jennison Associates LLC acquired a new stake in shares of Maravai LifeSciences in the 1st quarter worth $3,415,000. 50.25% of the stock is owned by hedge funds and other institutional investors.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
- Five stocks we like better than Maravai LifeSciences
- What Are the FAANG Stocks and Are They Good Investments?
- Brinker International’s Price Dip is an Appetizing Entry Point
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 3 Stocks That Could Beat the September Blues
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.